Program
mevrometostat
Also written as “PF-06821497”, “Mevrometostat (PF-06821497)” and “Mevrometostat”.
In Pfizer's pipeline, EZH2 inhibitor
. Its studies are mostly in Prostatic Neoplasms · Small Cell Lung Carcinoma, led by Pfizer.
Furthest: phase 3, since Jul 25, 20247 company-led studies, 4 open or runningNext primary completion: Feb 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 74 open or running | phase 3since Jul 25, 2024 | Feb 12, 2018 | Feb 28, 2027phase 3 · NCT06551324 |
- Named in Pfizer’s own pipeline as
mevrometostat PF-06821497
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2018First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT03460977 · 453 planned · United States, Bulgaria, China and more
- Mar 2, 2023Phase 1 study in HealthyNCT05767905 · 18 enrolled · United States
- Apr 12, 2024Phase 1 study in Healthy ParticipantsNCT06392230 · 6 enrolled · Netherlands
- Jul 25, 2024Phase 3 study in Prostatic NeoplasmsNCT06551324 · 609 enrolled · United States, Argentina, Australia and more
- Sep 10, 2024Phase 3 study in Metastatic Castration-Resistant Prostate CancerNCT06629779 · 900 planned · United States, Argentina, Brazil and more
- Oct 24, 2024Phase 1 study in HealthyNCT06661694 · Belgium
- Apr 15, 2025Phase 3 study in Prostatic NeoplasmsNCT07028853 · 1,000 planned · United States, Argentina, Australia and more
- Oct 30, 2026Primary completion moved from 2026-12-28 to 2027-02-28Date moved laterphase 3 · +2 months · NCT06551324
- Oct 30, 2026Primary completion moved from 2026-12-02 to 2027-09-30Date moved laterphase 3 · +10 months · NCT06629779
Ahead
- Feb 28, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06551324
- Sep 30, 2027Primary completion: phase 3 study in Metastatic Castration-Resistant Prostate CancerNCT06629779
- Apr 20, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT03460977
- Sep 12, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07028853
TargetBeta
“EZH2 inhibitor”the company's pipeline, read by Claude · source
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, mevrometostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specificall…”NCIt, read by Claude
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zeprumetostatrule | Jiangsu HengRui Medicine | phase 3 | 17 |
| TR115rule | tarapeutics-science-inc | phase 3 | 3 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07028853Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Sep 12, 2028 | 1,000 |
| NCT06661694Healthy · Belgium | 1 | Withdrawn | Sep 8, 2025 | 0 |
| NCT06629779Metastatic Castration-Resistant Prostate Cancer · United States, Argentina, Brazil and more | 3 | Recruiting | Sep 30, 2027 | 900 |
| NCT06551324Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 28, 2027 | 609 |
| NCT06392230Healthy Participants · Netherlands | 1 | Completed | Nov 11, 2024 | 6 |
| NCT05767905Healthy · United States | 1 | Completed | Jun 20, 2023 | 18 |
| NCT03460977Small Cell Lung Carcinoma · United States, Bulgaria, China and more | 1 | Recruiting | Apr 20, 2028 | 453 |
How it is read
Names in the registry
- “PF-06821497”, 2 entries
- “Mevrometostat (PF-06821497)”, 1 entry
- “Mevrometostat”, 1 entry
- “PF-06821497 Treatment A”, 1 entry
- “PF-06821497 Treatment B”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.